The content is available as a PDF (277.9 KB).
editorial . 2021 Mar 22:ciab220. doi: 10.1093/cid/ciab220
Remdesivir: An antiviral still seeking a raison d'être
Nathan W Cummins
1,✉
Nathan W Cummins
1
Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA
Find articles by Nathan W Cummins
1
Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA
✉
Corresponding author information: Nathan W. Cummins, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905. Phone: (507)284-3747. Email: cummins.nathan@mayo.edu
Received 2021 Mar 2.
Keywords: Remdesivir, Ebola Virus Disease, COVID-19
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
PMCID: PMC8083721 PMID: 33749746